miR-181b as a Potential Molecular Target for Anticancer Therapy of Gastric Neoplasms |
Guo, Jian-Xin
(Cancer Chemotherapy Center, The First People Hospital of Ningbo)
Tao, Qing-Song (Cancer Chemotherapy Center, Yinzhou People Hospital) Lou, Peng-Rong (Cancer Chemotherapy Center, Yinzhou People Hospital) Chen, Xiao-Chun (Cancer Chemotherapy Center, Yinzhou People Hospital) Chen, Jun (Cancer Chemotherapy Center, Yinzhou People Hospital) Yuan, Guang-Bo (Cancer Chemotherapy Center, Yinzhou People Hospital) |
1 | Asangani IA, Rasheed SA, Nikolova DA, et al (2008). MicroRNA-21 (miR-21) post-transcriptionally downregulates tumor suppressor Pdcd4 and stimulates invasion, intravasation and metastasis in colorectal cancer. Oncogene, 27, 2128-36. DOI ScienceOn |
2 | Bartel DP (2004). MicroRNAs: genomics, biogenesis, mechanism, and function. Cell, 116, 281-97. DOI ScienceOn |
3 | Chen G, Zhu W, Shi D, et al (2010). MicroRNA-181a sensitizes human malignant glioma U87MG cells to radiation by targeting Bcl-2. Oncol Rep, 23, 997-1003. |
4 | Connolly E, Melegari M, Landgraf P, et al (2008). Elevated expression of the miR-17-92 polycistron and miR-21 in hepadnavirus-associated hepatocellular carcinoma contributes to the malignant phenotype. Am J Pathol, 173, 856-64. DOI ScienceOn |
5 | Garzon R, Calin GA, Croce CM (2009). MicroRNAs in Cancer. Annu Rev Med, 60, 167-79. DOI |
6 | Gu P, Xing X, Tanzer M, et al (2008). Frequent loss of TIMP-3 expression in progression of esophageal and gastric adenocarcinomas. Neoplasia, 10, 563-72. DOI |
7 | Ji J, Shi J, Budhu A, et al (2009a). MicroRNA expression, survival, and response to interferon in liver cancer. N Engl J Med, 361, 1437-47. DOI ScienceOn |
8 | Ji J, Yamashita T, Budhu A, et al (2009b). Identification of microRNA-181 by genome-wide screening as a critical player in EpCAM-positive hepatic cancer stem cells. Hepatology, 50, 472-80. DOI |
9 | Kasinski AL, Slack FJ (2011). Epigenetics and genetics. MicroRNAs en route to the clinic: progress in validating and targeting microRNAs for cancer therapy. Nat Rev Cancer, 11, 849-64. DOI ScienceOn |
10 | Kim JH, Jung EJ, Lee HS, et al (2009). Comparative analysis of DNA methylation between primary and metastatic gastric carcinoma. Oncol Rep, 21, 1251-9. |
11 | Krichevsky AM, Gabriely G (2009). miR-21: a small multifaceted RNA. J Cell Mol Med, 13, 39-53. |
12 | Leung WK, To KF, Chu ES, et al (2005). Potential diagnostic and prognostic values of detecting promoter hypermethylation in the serum of patients with gastric cancer. Br J Cancer, 92, 2190-4. DOI ScienceOn |
13 | Lu J, He ML, Wang L, et al (2011). MiR-26a inhibits cell growth and tumorigenesis of nasopharyngeal carcinoma through repression of EZH2. Cancer Res, 71, 225-33. DOI ScienceOn |
14 | Mohammed FF, Smookler DS, Taylor SE, et al (2004). Abnormal TNF activity in Timp3-/- mice leads to chronic hepatic inflammation and failure of liver regeneration. Nat Genet, 36, 969-77. DOI |
15 | Sun T, Yang M, Chen S, et al (2011). The altered expression of MiR-221/-222 and MiR-23b/-27b is associated with the development of human castration resistant prostate cancer. Prostate, 72, 1093-103. |
16 | Ueda T, Volinia S, Okumura H, et al (2010). Relation between microRNA expression and progression and prognosis of gastric cancer: a microRNA expression analysis. Lancet Oncol, 11, 136-46. DOI ScienceOn |
17 | Wang B, Hsu SH, Majumder S, et al (2010a). TGFbetamediated upregulation of hepatic miR-181b promotes hepatocarcinogenesis by targeting TIMP3. Oncogene, 29, 1787-97. DOI |
18 | Wang J, Wang Q, Liu H, et al (2010b). MicroRNA expression and its implication for the diagnosis and therapeutic strategies of gastric cancer. Cancer Lett, 297, 137-43. DOI |
19 | Wang Y, Yu Y, Tsuyada A, et al (2011). Transforming growth factor-beta regulates the sphere-initiating stem cell-like feature in breast cancer through miRNA-181 and ATM. Oncogene, 30, 1470-80. DOI |
20 | Wu WK, Lee CW, Cho CH, et al (2010). MicroRNA dysregulation in gastric cancer: a new player enters the game. Oncogene, 29, 5761-71. DOI |
![]() |